{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:10:35Z","timestamp":1789096235838,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Primary hyperparathyroidism (PHPT) is a common and symptomatic endocrine disorder in India. There has been a notable rise in asymptomatic PHPT (urban India), creating a dilemma in optimal treatment approach\u2014surgery or medical management. Cinacalcet is a calcimimetic used in managing PHPT, but data regarding its use from India is limited. This retrospective study aimed to assess the prevalence of asymptomatic PHPT, compare symptomatic versus asymptomatic PHPT and evaluate the real-world outcomes among patients managed with parathyroidectomy (PTX) or cinacalcet.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A retrospective analysis was conducted on 90 PHPT patients seen between January 2020 and July 2024 at a tertiary care centre in New Delhi, India. Clinical, biochemical and imaging data were collected, and real-world outcomes were assessed for PTX and cinacalcet. Statistical analysis was performed using SPSS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Of the 90 patients, 64.4% were symptomatic and 35.6% were asymptomatic. Symptomatic patients had higher parathyroid hormone (PTH) levels and more frequent MIBI localization. PTX was curative and led to significantly greater reductions in calcium (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.006) and PTH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.009). Conversely, cinacalcet use was associated with normalization of calcium (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) and lowering of PTH (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.001) in both symptomatic and asymptomatic patients, with minimal side effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>A significant proportion of cases were asymptomatic PHPT, with biochemical and radiological profiles closely resembling those of symptomatic cases. While PTX provided definitive cure, cinacalcet led to short-term normalization of calcium and reduction of PTH. Cinacalcet serves as an alternative for patients who refuse surgery, are not candidates for surgery, or prefer medical management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijem.ijem_904_25","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T17:01:54Z","timestamp":1788195714000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cinacalcet and Parathyroidectomy Outcomes in Symptomatic and Asymptomatic Primary Hyperparathyroidism: A Retrospective Observational Study"],"prefix":"10.4103","volume":"30","author":[{"given":"Aditya","family":"Dutta","sequence":"first","affiliation":[{"name":"Department of Endocrinology, Max Super Speciality Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praphulla","family":"Koirala","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Max Super Speciality Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nupoor","family":"Vaghasia","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Max Super Speciality Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Allawadi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Max Super Speciality Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambrish","family":"Mithal","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Max Super Speciality Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"R1-20260911","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1046\/j.0007-1323.2001.01775.x","article-title":"Unique clinical characteristics of primary hyperparathyroidism in India","volume":"88","author":"Mishra","year":"2001","journal-title":"Br J Surg"},{"key":"R2-20260911","doi-asserted-by":"crossref","first-page":"29","DOI":"10.5144\/0256-4947.2005.29","article-title":"Primary hyperparathyroidism in north India: A description of 52 cases","volume":"25","author":"Bhansali","year":"2005","journal-title":"Ann Saudi Med"},{"key":"R3-20260911","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/0022-3859.65279","article-title":"Clinical profile of primary hyperparathyroidism from western India: A single center experience","volume":"56","author":"Gopal","year":"2010","journal-title":"J Postgrad Med"},{"key":"R4-20260911","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.4103\/2230-8210.119574","article-title":"Primary hyperparathyroidism in India: A cocktail of contemporary and classical presentations: Lesson from 47 cases","volume":"17","author":"Maskey","year":"2013","journal-title":"Indian J Endocrinol Metab"},{"key":"R5-20260911","first-page":"694","article-title":"Changes in clinical & biochemical presentations of primary hyperparathyroidism in India over a period of 20 years","volume":"139","author":"Shah","year":"2014","journal-title":"Indian J Med Res"},{"key":"R6-20260911","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4103\/2230-8210.190560","article-title":"Clinical and laboratory profile of primary hyperparathyroidism in Kashmir Valley: A single-center experience","volume":"20","author":"Misgar","year":"2016","journal-title":"Indian J Endocrinol Metab"},{"key":"R7-20260911","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1007\/s00774-017-0833-8","article-title":"Primary hyperparathyroidism: Insights from the Indian PHPT registry","volume":"36","author":"Bhadada","year":"2018","journal-title":"J Bone Miner Metab"},{"key":"R8-20260911","doi-asserted-by":"crossref","first-page":"73","DOI":"10.4103\/ijem.ijem_208_22","article-title":"Clinicopathological profile of primary hyperparathyroidism with special reference to Ki-67 labelling index","volume":"27","author":"Thanveer","year":"2023","journal-title":"Indian J Endocrinol Metab"},{"key":"R9-20260911","doi-asserted-by":"crossref","first-page":"S418","DOI":"10.4103\/2230-8210.104114","article-title":"Study of primary hyperparathyroidism","volume":"16","author":"Girish","year":"2012","journal-title":"Indian J Endocrinol Metab"},{"key":"R10-20260911","doi-asserted-by":"crossref","first-page":"581","DOI":"10.4158\/EP14447.OR","article-title":"Asymptomatic primary hyperparathyroidism exists in North India: Retrospective data from 2 tertiary care centers","volume":"21","author":"Mithal","year":"2015","journal-title":"Endocr Pract"},{"key":"R11-20260911","doi-asserted-by":"crossref","first-page":"355","DOI":"10.4103\/ijem.IJEM_445_16","article-title":"Five-year retrospective study on primary hyperparathyroidism in South India: Emerging roles of minimally invasive parathyroidectomy and preoperative localization with methionine positron emission tomography-computed tomography scan","volume":"22","author":"Mallikarjuna","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R12-20260911","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3897\/folmed.66.e117637","article-title":"Emerging pattern of asymptomatic hyperparathyroidism in South India-A six-year retrospective study","volume":"66","author":"Viswanathan","year":"2024","journal-title":"Folia Med (Plovdiv)"},{"key":"R13-20260911","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"key":"R14-20260911","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.12.003","article-title":"Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010)","volume":"73","author":"Griebeler","year":"2015","journal-title":"Bone"},{"key":"R15-20260911","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.2169\/internalmedicine.53.2133","article-title":"A pilot study to examine the management of asymptomatic hyperparathyroidism in Japanese patients in accordance with the guidelines for asymptomatic PHPT proposed at the Third International Workshop in 2008","volume":"53","author":"Ogo","year":"2014","journal-title":"Intern Med"},{"key":"R16-20260911","first-page":"1360","article-title":"Changing paradigms in the surgical management of hyperparathyroidism at a tertiary care hospital in a developing country","volume":"69","author":"Siddiqui","year":"2019","journal-title":"J Pak Med Assoc"},{"key":"R17-20260911","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1530\/EC-21-0382","article-title":"Changes in clinical patterns of Chinese patients with primary hyperparathyroidism in the past 12 years: A single-center experience","volume":"10","author":"Liu","year":"2021","journal-title":"Endocr Connect"},{"key":"R18-20260911","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00774-020-01142-w","article-title":"Progressive rise in the prevalence of asymptomatic primary hyperparathyroidism in India: Data from PHPT registry","volume":"39","author":"Arya","year":"2021","journal-title":"J Bone Miner Metab"},{"key":"R19-20260911","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"Evaluation and management of primary hyperparathyroidism: Summary statement and guidelines from the Fifth International Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Mineral Res"},{"key":"R20-20260911","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1210\/jc.2009-1472","article-title":"Cinacalcet treatment of primary hyperparathyroidism: Biochemical and bone densitometric outcomes in a five-year study","volume":"94","author":"Peacock","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R21-20260911","doi-asserted-by":"crossref","first-page":"E9","DOI":"10.1210\/jc.2010-1221","article-title":"Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity","volume":"96","author":"Peacock","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"R22-20260911","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1590\/S0004-27302006000400011","article-title":"From mild to severe primary hyperparathyroidism: The Brazilian experience","volume":"50","author":"Bandeira","year":"2006","journal-title":"Arq Bras Endocrinol Metabol"},{"key":"R23-20260911","doi-asserted-by":"crossref","first-page":"648","DOI":"10.9738\/INTSURG-D-14-00094.1","article-title":"A 20-year study on 190 patients with primary hyperparathyroidism in a developing country: Turkey experience","volume":"100","author":"Usta","year":"2015","journal-title":"Int Surg"},{"key":"R24-20260911","doi-asserted-by":"crossref","first-page":"30","DOI":"10.2967\/jnmt.107.044040","article-title":"Differences in accuracy of 99mTc-sestamibi scanning between severe and mild forms of primary hyperparathyroidism","volume":"36","author":"Bandeira","year":"2008","journal-title":"J Nucl Med Technol"},{"key":"R25-20260911","first-page":"105","article-title":"Primary hyperparathyroidism in developing world: A systematic review on the changing clinical profile of the disease","volume":"64","author":"Yadav","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"R26-20260911","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/jbmr.4685","article-title":"The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: A systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Ye","year":"2022","journal-title":"J Bone Mineral Res"},{"key":"R27-20260911","doi-asserted-by":"crossref","first-page":"485","DOI":"10.4103\/ijem.IJEM_684_17","article-title":"Cinacalcet: A viable therapeutic option for primary hyperparathyroidism in the elderly","volume":"22","author":"Abusahmin","year":"2018","journal-title":"Indian J Endocrinol Metab"},{"key":"R28-20260911","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1530\/EC-21-0258","article-title":"A single-centre retrospective analysis of cinacalcet therapy in primary hyperparathyroidism 2021","volume":"10","author":"Bell","year":"2021","journal-title":"Endocr Connect"},{"key":"R29-20260911","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"},{"key":"R30-20260911","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Indian Journal of Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_904_25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T03:00:15Z","timestamp":1789095615000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijem.ijem_904_25"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ijem.ijem_904_25","relation":{},"ISSN":["2230-8210","2230-9500"],"issn-type":[{"value":"2230-8210","type":"print"},{"value":"2230-9500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2025-09-27","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}